New York State Common Retirement Fund lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 292,555 shares of the company’s stock after selling 5,039 shares during the period. New York State Common Retirement Fund’s holdings in Axsome Therapeutics were worth $9,643,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in AXSM. Affinity Asset Advisors LLC boosted its holdings in shares of Axsome Therapeutics by 150.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 25,000 shares of the company’s stock worth $1,687,000 after buying an additional 15,000 shares during the period. Baldwin Brothers LLC MA boosted its holdings in shares of Axsome Therapeutics by 68.4% during the 3rd quarter. Baldwin Brothers LLC MA now owns 41,845 shares of the company’s stock worth $1,379,000 after buying an additional 17,000 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $37,367,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Axsome Therapeutics by 1.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 186,095 shares of the company’s stock worth $12,554,000 after buying an additional 3,253 shares during the period. Finally, Citigroup Inc. boosted its holdings in shares of Axsome Therapeutics by 26.9% during the 2nd quarter. Citigroup Inc. now owns 7,582 shares of the company’s stock worth $512,000 after buying an additional 1,608 shares during the period. 60.23% of the stock is owned by institutional investors.
In other Axsome Therapeutics news, Director Roger Jeffs bought 3,950 shares of Axsome Therapeutics stock in a transaction on Friday, November 19th. The shares were purchased at an average cost of $37.30 per share, with a total value of $147,335.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mark E. Saad bought 3,000 shares of Axsome Therapeutics stock in a transaction on Wednesday, November 17th. The shares were acquired at an average cost of $34.53 per share, for a total transaction of $103,590.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 7,477 shares of company stock worth $269,634 over the last ninety days. 26.10% of the stock is currently owned by insiders.
Shares of NASDAQ:AXSM opened at $37.78 on Monday. The firm has a 50 day moving average of $36.81 and a 200-day moving average of $40.81. The stock has a market capitalization of $1.42 billion, a PE ratio of -11.28 and a beta of 2.22. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 1.15. Axsome Therapeutics, Inc. has a 12 month low of $19.38 and a 12 month high of $84.73.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 8th. The company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.02. During the same quarter in the prior year, the business earned ($0.58) EPS. On average, research analysts predict that Axsome Therapeutics, Inc. will post -3.5 EPS for the current fiscal year.
Several analysts recently commented on AXSM shares. Mizuho reduced their target price on shares of Axsome Therapeutics from $55.00 to $51.00 and set a “buy” rating for the company in a report on Thursday, November 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a research note on Tuesday, November 9th. SVB Leerink dropped their price objective on shares of Axsome Therapeutics from $75.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, November 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, September 15th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $95.89.
Axsome Therapeutics Profile
Axsome Therapeutics, Inc engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Recommended Story: Limitations of the P/E Growth ratio
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Want More Great Investing Ideas?